24 May 2013
Keywords: merck, kgaa, forging, ahead, erbitux, germany, success
Article | 05 August 2002
For Germany's Merck KGaA, the success of Erbitux (cetuximab), for whichit holds development and marketing rights outside North America, is
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
5 August 2002
© 2013 thepharmaletter.com